To examine T cell function in MPN progression, we depleted CD4+ and CD8+ T cell populations, using CD4/CD8 specific antibodies, (Supplementary Figure S 5A, B) in mice that had received CALRdel52MPL-BM and treated these with a TGF-β neutralizing antibody. This evidence concerns the gene CD8A and myeloproliferative neoplasm.